Diamond Therapeutics

What Diamond Therapeutics does

Diamond Therapeutics Inc. is a Toronto-based, privately held clinical-stage pharmaceutical company founded in 2018 that develops sub-perceptual psilocybin-based medicines and psychedelic-derived therapies for neuropsychiatric conditions. Its lead clinical program is a low-dose psilocybin therapy for demoralization in mood disorders, which has completed Phase 1 in healthy subjects and is currently in FDA-authorized and Health Canada-approved Phase 2 trials conducted at the University of Alabama at Birmingham under investigator Dr. Peter Hendricks. The company's scientific differentiation rests on a dosing strategy designed to eliminate hallucinogenic side effects, enabling administration to a broad patient cohort without the supervised hallucinogenic experience required by full-dose psychedelic protocols.

The platform extends beyond psilocybin to include a diverse pipeline of tryptamine analogs and small organic molecules that modulate selective serotonin receptors and neurotrophic receptor signalling, plus a low-dose LSD research program under a 2022 agreement with McGill University. Supporting IP includes five US-issued patents listing Dr. Jeffrey Sprouse as inventor and thirteen patents/applications tied to scientific advisor Dr. Paul Glue. Development is backed by a scientific advisory board drawn from Northwestern, Baylor, Otago, Hannover Medical School, and former Pfizer, Lundbeck, Allergan, and Teva executives.

The business model is a traditional clinical-stage pharmaceutical model: the company is pre-revenue, funds operations through a mix of venture capital (notably First Avenue Ventures Life Science Fund I in April 2023), Canadian institutional support (Ontario Brain Institute, CABHI's CAD $2.8 million award in November 2025), and US non-dilutive grants (Southern Research in 2024 and ARPA-H in 2026), with the intent to seek FDA, EMA, and Health Canada approval for eventual commercialization through prescription and specialty pharmaceutical channels. With 1-10 employees and a CEO/founder (Judy Blumstock) whose background is in life-sciences venture capital rather than commercial pharma operations, the company is structured as a clinical-development platform whose eventual commercial path (in-house launch versus out-licensing) has not been publicly disclosed.

Name

Diamond Therapeutics

Legal name

Diamond Therapeutics, Inc.

Website

https://diamondthera.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

Diamond Therapeutics is a Toronto-based, clinical-stage pharmaceutical company developing sub-perceptual psilocybin and psychedelic-derived therapies for patients with neuropsychiatric conditions, led by a Phase 2 program in demoralization and a broader tryptamine and low-dose LSD pipeline.

Ownership category

akta.pro rank

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Drug Development: Pre-revenue pharmaceutical company developing psilocybin-based and psychedelic-derived therapies. Revenue generation will come from FDA, EMA, and Health Canada approved psychedelic medicines commercialized through traditional pharmaceutical channels upon successful clinical trial completion.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Diamond Therapeutics is a clinical-stage pharmaceutical company developing sub-perceptual psilocybin-based medicines and a pipeline of tryptamine analogs and small organic molecules for neuropsychiatric conditions. Its lead clinical program is a low-dose psilocybin therapy for demoralization in mood disorders, with Phase 1 completed and Phase 2 trials authorized by the FDA and approved by Health Canada. The company's stated goal is to develop psychedelic-derived therapies that surpass current first-line mental health treatments in efficacy, speed of onset, safety and tolerability.

Product overview

Diamond Therapeutics is a Toronto-based pharmaceutical company developing a portfolio of psychedelic-derived therapies for mental health conditions. The company's core offering is sub-perceptual psilocybin-based medicines that have received FDA, EMA, and Health Canada approvals for clinical development. The lead product is a low-dose psilocybin therapy for demoralization in mood disorders, which has completed Phase 1 and entered Phase 2 clinical trials. Beyond psilocybin, the company is advancing a pipeline of tryptamine analogs and small organic molecules that modulate selective serotonin receptors and neurotrophic receptor signaling. A separate research program with McGill University explores low-dose LSD. The company positions its approach as surpassing current first-line treatments in efficacy, speed of onset, safety, and tolerability.

Differentiator

Problem solved

Functional benefit

Products and services

• Sub-perceptual psilocybin-based medicines FDA, EMA and Health Canada regulated therapies for neuropsychiatric conditions using sub-perceptual (non-hallucinogenic) doses of psilocybin. Designed to deliver rapid therapeutic outcomes without perceptual side effects, enabling administration to a broad cohort of patients.
• Low-dose psilocybin therapy for demoralization in mood disorders Clinical-stage low-dose psilocybin program targeting demoralization in mood disorders. Phase 1 completed in healthy subjects; Phase 2 authorized by FDA and approved by Health Canada.
• Low-dose psilocybin therapy for anxiety Phase 2 clinical-stage low-dose psilocybin program targeting anxiety, supported by US government non-dilutive funding.
• Tryptamine analogs pipeline Diverse pipeline of tryptamine analogs and small organic molecules that act by modulating selective serotonin receptors and neurotrophic receptor signalling for neuropsychiatric conditions.
• Low-dose LSD research program Research-stage program on low-dose LSD conducted in partnership with McGill University, expanding the company's psychedelic-derived therapy portfolio.

Quantifiable outcome

• Phase I clinical study completed for low-dose psilocybin in healthy human subjects
• +1 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core and minor.

• University of Alabama at BirminghamcoreStrategic or Co-development PartnerUniversity of Alabama at Birmingham serves as the clinical trial site for Diamond Therapeutics' FDA-authorized study evaluating low-dose psilocybin in human subjects with demoralization. The trial is led by researcher Dr. Peter Hendricks and conducted under FDA authorization.
• McGill UniversityminorStrategic or Co-development PartnerDiamond Therapeutics signed an agreement with McGill University for research on low-dose LSD, expanding the company's psychedelic research portfolio beyond psilocybin.
• BioPharma ServicesminorStrategic or Co-development PartnerDiamond Therapeutics contracted BioPharma Services for Phase 1 clinical trial services for low-dose psilocybin studies in healthy human subjects.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Compass Pathways: Publicly listed developer of psilocybin therapy for treatment-resistant depression, currently in late-stage clinical trials. Most directly comparable to Diamond as a psilocybin-focused CNS drug developer targeting mental-health indications.
• MindMed (Mind Medicine): Publicly listed psychedelic-inspired medicine company developing LSD-based and other psychedelic-derived therapies for anxiety, ADHD, and other CNS indications. Direct competitor in psychedelic drug development with overlapping mental-health focus.
• GH Research: Publicly listed clinical-stage company developing mebufotenin and other psychedelic-based therapies for treatment-resistant depression. Direct peer in psychedelic drug development with a similar IND/CTA-stage regulatory profile.
• atai Life Sciences: Publicly listed clinical-stage biopharmaceutical company developing psychedelic and complementary therapies for mental health, with a broad portfolio approach across multiple compounds and indications. Comparable in target indications and psychedelic mechanism of action.
• Cybin: Publicly listed clinical-stage psychedelic therapeutics company developing psilocybin analogs and deuterated tryptamines for depression and addiction. Direct competitor in sub-perceptual and next-generation psychedelic chemistry.
• Beckley Psytech: Private clinical-stage psychedelic drug developer (acquired by atai in 2023) focused on short-duration psychedelic formulations for CNS indications. Comparable in psychedelic mechanism and clinical-stage mental health focus.
• Small Pharma: Clinical-stage developer of DMT-based therapies for depression (acquired by atai in 2023). Comparable as a tryptamine-based drug developer targeting mental-health indications with a similar regulatory stage.

Emerging players

• Field Trip Health: Operator of psychedelic-assisted therapy clinics in North America and Europe. Adjacent to Diamond — focused on delivery of psychedelic treatments rather than drug development, but shares the mental-health psychedelic thesis and overlapping patient base.

Broad incumbents

• Otsuka Pharmaceutical: Large established pharmaceutical company with a significant CNS and mental-health portfolio (including depression and schizophrenia franchises). Comparable as a potential strategic acquirer or commercialization partner for Diamond given its existing CNS commercial infrastructure.
• Lundbeck: Global pharmaceutical company with deep CNS and psychiatry franchise, where Diamond's pipeline head Dr. Jeffrey Sprouse previously led psychiatry drug discovery. Comparable as a strategic acquirer/partner with direct expertise in the therapeutic area Diamond is targeting.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/DiamondThera
• LinkedInlinkedin.com/company/diamond-therapeutics

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds5 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Diamond Therapeutics